Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0461929603
Mon, 27.05.2024
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Alliance/Merger
Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH
27.05.2024 / 07:00 CET/CEST
Zurich, 27th of May 2024: Xlife Sciences AG announces the merger of its portfolio company, palleos healthcare GmbH, with OCT Clinical GmbH. This [ … ]
Tue, 23.04.2024
Xlife Sciences AG
Zurich, 23rd of April 2024: Xlife Sciences AG (SIX: XLS) reports on the financial and operational results of 2023 and provides insights into plans for 2024. Despite global uncertainties, the company remains resilient thanks to innovative projects and strategic partnerships, managing to complete its first cash-effective exits.
Operational Progress i [ … ]
Mon, 05.02.2024
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Alliance/Letter of Intent
Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City
05.02.2024 / 07:00 CET/CEST
Xlife Sciences AG is excited to announce the expansion of its existing collaboration with the Departme [ … ]
Fri, 29.12.2023
Xlife Sciences AG
Zurich, 29th of December 2023: VERAXA Biotech AG, a pioneering company in the development of superior antibody-based cancer therapies and a portfolio company of Xlife Sciences AG (SIX: XLS), is proud to announce the acquisition of Synimmune GmbH and its innovative Phase I antibody (FLYSYN) for the treatment of Acute Myeloid Leukemia (AML). This mar [ … ]
Fri, 22.12.2023
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Research Update/Study
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases
22.12.2023 / 07:00 CET/CEST
Xlife Sciences AG is pleased to announce that its project company, x-nuclear diagnostics GmbH, has reached a decisive milestone in [ … ]
Wed, 20.12.2023
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Letter of Intent/Partnership
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases
20.12.2023 / 07:00 CET/CEST
Xlife Sciences AG (SIX: XLS) and Quant Biomarke [ … ]
Mon, 18.12.2023
Xlife Sciences AG
Zurich, 18th of December 2023: Xlife Sciences AG (SIX: XLS) achieves EU MDR Class IIa registration with the portfolio company FUSE-AI GmbH and reaches a milestone for medical technology. The AI algorithm «Prostate.Carcinoma.ai» from FUSE-AI GmbH can analyze a multitude of radiological images in a very short time with a lower error rate than the hum [ … ]
Wed, 18.10.2023
Xlife Sciences AG
Zurich, 18th of October 2023: Xlife Sciences AG (SIX: XLS) has secured a strategic collaboration with 4D Lifetec AG that marks a transformative phase in the healthcare sector, fusing financial capabilities with avant-garde technology, aimed at revolutionizing early cancer detection.
The agreement involves a two-pronged approach: Firstly, 4D Lifete [ … ]
Fri, 29.09.2023
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Sustainability/ESG
ESG Report shows status quo and outlines path for future sustainability improvements
Media Release
Zurich, September 29, 2023
29.09.2023 / 07:00 CET/CEST
Xlife Sciences (SIX: XLS) today published its inaugural report on Environmental, Social and Governance ( [ … ]
Thu, 21.09.2023
Xlife Sciences AG
Xlife Sciences (SIX: XLS) today reported on its operational progress in H1 2023 and published its key financial figures for the reporting period. Xlife Sciences’ full half-year report 2023 is available for download as a PDF document at https://www.xlifesciences.ch/en/news-and-key-figures in the “Financial Reports” section.
Operational Highlights [ … ]